全球织网，越战越勇。 文 ｜ 韩璐 编辑 ｜ 鄢子为 以下文章来源于21世纪商业评论 ，作者韩璐 21世纪商业评论 . 《21世纪商业评论》敏感于一切商业新知、商业产品、商业模式和商业英雄，敏感于新公司的新玩意、老公司的新改造、旧话题的新表达、老商业的新颠 覆，为您提供最新鲜实用的商业养分。 来源｜ 21世纪商业评论（ID：weixin21cbr） 封面来源 ｜ 视觉中国 李嘉诚，卖药大赚一笔。 3月5日晚，旗下和黄医药公布，2025年营收约合38亿元人民币，净利超过30亿元，同比暴增11倍。净利激增，得益于一笔股权交易的一次性收益。 论资产组合，和黄医药在李家的分量有限。 其市值约170亿元人民币，李嘉诚控制的长和，持有约四成股权，价值仅70亿元。 和黄医药管理层称，旗下抗体靶向偶联药物平台（ATTC），已有两款产品进入全球开发阶段，正积极寻找伙伴，推进海外开发。 全球织网 李嘉诚家族的医药生意，重心更多在海外。 2025年，在主力产品的销售额上，和黄医药在海外地区，揽获超25亿人民币，大幅增长26%左右。 目前，和黄医药共有4款商业化的创新药——呋喹替尼、索凡替尼、赛沃替尼以及他则司他。 李嘉诚家族投资新 ...

Core Viewpoint - Li Ka-shing's company, Hutchison Whampoa, has made significant profits from its pharmaceutical business, particularly through a recent equity transaction that boosted net profits dramatically [5][24]. Group 1: Financial Performance - Hutchison Whampoa's revenue for 2025 is projected to be approximately 3.8 billion RMB, with net profits exceeding 3 billion RMB, marking an 11-fold increase year-on-year [5]. - The company's market capitalization is around 17 billion RMB, with Li Ka-shing's controlling entity holding about 40% of the shares, valued at 7 billion RMB [8]. - The company has reported a significant increase in overseas sales, expected to exceed 2.5 billion RMB, reflecting a growth of approximately 26% [10]. Group 2: Product Pipeline and Development - Hutchison Whampoa has four commercialized innovative drugs, including Furazolidone, which has been notably successful, generating overseas sales of about 2.5 billion RMB last year [13]. - The company is advancing its antibody-drug conjugate platform (ATTC), with two products already in global development stages and plans to initiate clinical trials for new candidates by the end of the year [33][36]. - The management has indicated that the oncology/immunology business revenue is expected to reach between 330 million to 450 million USD by 2026 [20]. Group 3: Strategic Adjustments and Future Plans - In early 2025, Hutchison Whampoa sold 45% of its stake in Shanghai Hutchison Pharmaceuticals for 4.5 billion RMB, allowing the company to focus on oncology and immunology drugs [23]. - The company has a cash reserve nearing 10 billion RMB, which will support ongoing projects and research and development efforts [30]. - Management is actively seeking new opportunities for collaboration and potential acquisitions to enhance the ATTC platform's global development [41].